+1 (888) 794-0077

Technical Expertise

ICH M10: Preview New Bioanalytical Method Validation Guidance

ICH M10: Preview New Bioanalytical Method Validation Guidance

The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) is in the process of revising M10, a multidisciplinary guideline that governs bioanalytical method validation. Drugs need to contain the correct...

Pathologists Can Move Your Drug Development Program Forward

Pathologists Can Move Your Drug Development Program Forward

Pathologists examine the causes and mechanisms of diseases and, in the world of drug development, that means collecting, processing and analyzing tissue for toxicity. Histotechnologists fix tissue samples onto slides, stain them to distinguish types of cells and cell...

WuXi AppTec Grows Biomarker Capabilities with Quanterix

WuXi AppTec Grows Biomarker Capabilities with Quanterix

The newest partnership between Quanterix and WuXi AppTec Laboratory Testing Division (LTD) integrates industry-leading instruments and reagents with world-class laboratory and technical staff to form the co-developed Simoa Joint Lab in Shanghai. Starting in 2021, drug...

How DMPK Lead Optimization Mitigates Risk and Conserves Resources

How DMPK Lead Optimization Mitigates Risk and Conserves Resources

Lead optimization in the world of drug development is a multifaceted process. It is a crucial part of discovery pharmacology and toxicology, as such, is used to identify and advance the most promising drug compounds. First and foremost, lead optimization aims to...

Virtual Tours Available Today

Virtual Tours Available Today

Explore our New Jersey facilities from wherever you are working, even the comfort of your own home. Virtually tour our New Jersey facilities in Cranbury and Plainsboro to learn about our Bioanalytical and DMPK capabilities and instrumentation to support your drug...

Transitioning to Phase I Clinical Trials

Transitioning to Phase I Clinical Trials

Developing biologic solutions is a complex process, and bridging bioanalytical assays from preclinical to phase I clinical trials is a demanding step in advancing your therapeutic. While maneuvering through regulatory requirements and intensive testing, it is easy for...

Dual Filing your IND Package: Planning Pays Off

Dual Filing your IND Package: Planning Pays Off

Navigating the Investigational New Drug (IND) submission process for your drug development program can be a complex process, especially when filing with various regulatory agencies and pursuing multiple markets. However, dual, or globally filing an IND package can...

ACT Annual Meeting: Managing Roadblocks to Success

ACT Annual Meeting: Managing Roadblocks to Success

One of the largest shares of preclinical testing in any drug development program is toxicology studies, yet bringing together the community supporting this pivotal development stage does not happen often enough. Fortunately, the 2020 American College of Toxicology...

Ramp Up: What Drug Developers Need to Know

Ramp Up: What Drug Developers Need to Know

Many drug development companies are prepared to move their programs forward and effectively submit preclinical packages to regulatory bodies. In the challenging business of drug development, disruptions and obstacles are elements that must be part of the conversation...